Why #SkinnyTok videos are being blocked on TikTok
TikTok has blocked the hashtag #SkinnyTok, following pressure from European officials. According to critics, videos under the hashtag promote disordered eating behaviours disguised as health advice.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
CBC
14 hours ago
- CBC
Why #SkinnyTok videos are being blocked on TikTok
TikTok has blocked the hashtag #SkinnyTok, following pressure from European officials. According to critics, videos under the hashtag promote disordered eating behaviours disguised as health advice.
National Post
a day ago
- National Post
What eating foods like dark chocolate and berries did to a study group of more than 120,000 people
A new study reveals what drinking tea and eating dark chocolate and berries did for a group of more than 120,000 people. Article content Those foods, as well as fruits like grapes, apples, oranges, and beverages like red wine, all contain flavonoids, which are compounds found in many plant products. Flavonoids can 'help your body function more efficiently while protecting it against everyday toxins and stressors,' per Healthline. The study's authors said those who consumed a diverse range of foods containing flavonoids (such as berries, grapes and dark chocolate) 'could lower their risk of developing serious health conditions and have the potential to live longer,' in a news release. The study has been peer-reviewed. Article content Article content Article content In the study, which was recently published in the journal Nature Food, researchers observed 124,805 participants between the ages of 40 and 70 from the UK Biobank, a large-scale database with biomedical information. The participants were tracked for roughly 10 years and their dietary information was collected using a questionnaire asking them about the frequency in which they ate approximately 200 types of food and 30 beverages. Article content Article content Dr. Benjamin Parmenter, a research fellow at Edith Cowan University in Australia, was the study's first author and co-lead. He said consuming roughly 500 mg of flavonoids a day or more was linked to a 16 per cent lower risk of 'all-cause mortality' (meaning death from any cause). Article content It was also linked to a roughly 10 per cent lower risk of cardiovascular disease, type 2 diabetes, and respiratory disease. Article content A study published in 2025 in peer-reviewed food science journal Foods said, as it pertains to human health, 'flavonoids are recognized for their ability to combat aging, mitigate inflammation, safeguard the nervous system, and promote overall well-being.' However, in another study published in 2022 in the Nutrition Journal, researchers 'observed an increased risk of prostate cancer by higher intake of total flavonoids.' In a study published in 2016 in the Journal of Nutritional Science, researchers called for further studies on flavonoids so their usefulness 'in the diet could be improved for better human health.' Article content Article content 'Over 30 different types of flavonoids are regularly consumed in the human diet. These are found in different types of everyday foods,' Parmenter told National Post over email. Article content Article content A few squares of dark chocolate could be roughly 25 mg of flavonoids. One apple is equal to roughly 100 mg of flavonoids, while one orange is roughly 60 mg. For tea drinkers, one cup of black tea is roughly 300 mg of flavonoids, while the same amount of green tea is roughly 150 mg. Article content 'We observed that consuming a higher quantity and wider diversity of dietary flavonoids, when consumed together, may represent the optimal approach for improving long-term health, compared with increasing either flavonoid quantity or diversity alone,' Parmenter said. Article content Those with the highest flavonoid diversity were more likely to be female, older, have a lower body mass index (BMI), be more physically active and have a higher education and were less likely to be current smokers, according to the study.
Globe and Mail
a day ago
- Globe and Mail
Novo Nordisk Stock: Is It Still a Smart Buy?
Much like the long-term users of its most popular product, Novo Nordisk 's (NYSE: NVO) stock has slimmed down considerably of late. Share prices of the company, which developed and sells weight loss drug Wegovy, have fallen nearly 18% in price since the start of this year. Popularity attracts competition, and investors are growing concerned that the Danish pharmaceutical giant won't be able to compete. I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. An increasingly crowded field Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, when Wegovy became the first GLP-1 drug specifically approved by the Food and Drug Administration (FDA) for that indication in mid-2021. Novo Nordisk's Ozempic was first, but it was used off-label as a weight-loss drug, and had only initially been approved as a diabetes treatment and kidney disease treatment. It's easy to believe in a company when it's riding high and unopposed. But late in 2023, a new entrant was approved -- mighty American pharmaceutical company Eli Lilly (NYSE: LLY) with its own GLP-1 treatment, Zepbound -- giving Novo Nordisk one of the strongest competitors imaginable. Almost certainly, this won't continue to be a two-car race for long. Other companies, both large and small, in the healthcare field are pushing hard to develop their own obesity drugs, with varying degrees of success. Eli Lilly alone is an intimidating presence. A mainstay on the American pharmaceutical scene, it's grown to a massive size, to the point where it's the most valuable pharmaceutical company in the world by market cap. It can leverage its vast resources to develop and market any kind of medicine it wants, and in the obesity segment, it was already nearly there with Zepbound's FDA-approved-for-diabetes sibling drug, Mounjaro. Since then, it seems Zepbound has carved out a significant market share from Wegovy. Precise figures are hard to come by, but according to a Goldman Sachs analysis recently reported by Barron's, Novo Nordisk is clinging to a 51% share of the roughly $28 billion market. Eli Lilly holds the rest. Fragmentation and setbacks Like other pharmaceutical industry pundits, Goldman Sachs is predicting that once other obesity drugs are developed successfully and approved, the market will fragment. That's a wholly believable prediction given the zeal and urgency behind many of those efforts. Meanwhile, Novo Nordisk has taken a series of competitive blows that reduced its lead. A shortage of semaglutide -- the main ingredient of Wegovy -- led the FDA to allow compounding pharmacies to make copies of the molecule, essentially producing new competition. Although the shortage is officially over, it showed that Novo Nordisk would be vulnerable if such a situation reoccurred. Another of the numerous fresh setbacks was a head-to-head clinical trial conducted by Eli Lilly, pitting Zepbound against Wegovy. Last December, the results of the study indicated notably more significant weight loss for participants using Wegovy. One internal development also dented investor sentiment on Novo Nordisk, and that was the company's announcement in mid-May that long-serving CEO Lars Fruergaard Jørgensen was stepping down. When enterprises are humming along pleasantly, they rarely experience a top leader's departure. Fighting back Novo Nordisk isn't just absorbing hurtful blows, though; it's been busy shoring up its defenses. As 2024 came to a close, it scooped up contract drug manufacturer Catalent, bringing Wegovy production more under its direct control. That $16.5 billion deal wasn't cheap by any yardstick, but if the new asset is managed well, it should be more than worth the cost ultimately. Novo Nordisk is also keeping up the pace with its own development activities, attempting to succeed with new medications and/or other indications for Wegovy. Its next-generation obesity treatment CagriSema was essentially a flop. However, the company has already had success winning FDA approval for the versatile Wegovy to treat liver disorder metabolic dysfunction-associated steatohepatitis (MASH), and it's developing the drug for a clutch of other ailments. It also has other medications for different disorders in its pipeline. Meanwhile, a score of researchers modeling the future of the obesity market feel that sales of such drugs will blast through the roof. Projections vary, but a typical one is the latest from Morgan Stanley. In May, the veteran investment bank upped its estimate for the market's peak (predicted to occur in 2035) to $150 billion, well up from its previous assumption of $105 billion. The former number is more than 6 times the $24 billion estimated sales of 2024. The very encouraging news for Novo Nordisk bulls like myself is that even if the market gets highly fragmented with numerous competing products and loses significantly more share -- unlikely, given its first-mover prominence and the strength of the Wegovy brand name -- it'll still be a player in a huge market. Yes, competition can be tough. There are a lot of prizes in this game, and more players are entering it. But I think this original player will manage to hold on and thrive, and I continue to consider Novo Nordisk stock a buy. Should you invest $1,000 in Novo Nordisk right now? Before you buy stock in Novo Nordisk, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Novo Nordisk wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor 's total average return is789% — a market-crushing outperformance compared to172%for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of June 2, 2025
